治疗复发难治多发性骨髓瘤的新疗法即将问世。

IF 2.5 3区 医学 Q2 HEMATOLOGY
Nadine Abdallah MD, Shaji K. Kumar MD
{"title":"治疗复发难治多发性骨髓瘤的新疗法即将问世。","authors":"Nadine Abdallah MD, Shaji K. Kumar MD","doi":"10.1016/j.hoc.2023.12.013","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma\",\"authors\":\"Nadine Abdallah MD, Shaji K. Kumar MD\",\"doi\":\"10.1016/j.hoc.2023.12.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":55060,\"journal\":{\"name\":\"Hematology-Oncology Clinics of North America\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology-Oncology Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0889858823001806\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889858823001806","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管治疗方法有所改进,但大多数多发性骨髓瘤(MM)患者仍会复发。一些新型药物在早期临床试验中显示出了活性和耐受性。Venetoclax 是一种 B 细胞淋巴瘤 2(Bcl-2)抑制剂,对有 t(11;14)和/或 Bcl-2 表达的患者有活性。Iberdomide和mezigdomide是脑龙E3连接酶调节剂,与来那度胺和泊马度胺相比,具有更高的效力、免疫调节和抗增生活性。它们在接受大量预处理的患者中显示出良好的活性。Modakafusp alfa 是一种免疫细胞因子,可将干扰素靶向 CD38+ 细胞。在 1 期治疗中,它已在复发/难治性 MM 中显示出单药活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信